Activa

Quick links to important sections

Activa

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Activa

Quick Facts

Property Description
Active Ingredient Diclofenac Sodium
Forms Tablets, Capsules, Suppositories, Gels, Injectable Solutions
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Origin Synthetic Phenylacetic acid derivative
General Purpose Relief from inflammation, pain, and fever

What Type of Medicine is Activa? (Identity, Class, and Composition)

Activa is a pharmaceutical preparation whose primary active component is Diclofenac Sodium, which classifies it as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This synthetic compound is chemically categorized as a phenylacetic acid derivative, placing it within a family of agents designed to manage the body's inflammatory response.

The drug's primary function is centered on its ability to inhibit the synthesis of prostaglandins, which are the chemical messengers responsible for initiating and sustaining pain and inflammatory signals. Diclofenac functions as a cyclooxygenase (COX) inhibitor. This pharmacological profile makes Activa an agent for providing combined analgesic (pain-relieving) and anti-inflammatory relief.


Activa: Available Forms and General Purpose

The Diclofenac Sodium found in Activa formulations is available in several dosage forms to accommodate various therapeutic requirements. These include oral formulations (such as tablets and capsules), rectal formulations, topical formulations (gels and solutions), and solutions for parenteral administration. This variety allows for both systemic action, affecting the body as a whole, and targeted local action at the specific site of application.

The general therapeutic purpose of Activa is to provide symptomatic relief by utilizing its properties to reduce inflammation, alleviate associated pain, and decrease fever resulting from underlying inflammatory processes. The active substance works to reduce swelling and ease physical discomfort, making the medication a choice for addressing both the sensation of pain and the physical manifestations of inflammation.

Regulatory References

  1. NIH StatPearls, Diclofenac
  2. MedlinePlus Drug Information, Diclofenac

What side effects are possible with Activa?

Possible side effects and safety information

The safety profile of Activa (Diclofenac Sodium) is categorized based on clinical trial data and post-marketing surveillance, as defined by government regulatory authorities.

Key adverse reaction categories include effects on the gastrointestinal (GI), cardiovascular, hepatobiliary (liver), and dermatological systems.


Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Effects
Common Headache, dizziness, nausea, vomiting, dyspepsia, abdominal pain, flatulence, rash, and increased liver transaminases.
Rare to Very Rare Hypersensitivity reactions (anaphylaxis), somnolence, gastrointestinal hemorrhage, melena, hepatitis, acute renal failure, and serious skin reactions like Stevens-Johnson Syndrome.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight two major serious adverse event categories: Cardiovascular Thrombotic Events and Gastrointestinal Events. The cardiovascular risk involves the potential for Myocardial Infarction (MI) and Stroke, which can be fatal. This risk may increase with higher dose and longer duration of use and can occur early in treatment. The serious GI risk includes bleeding, ulceration, and perforation of the GI tract, which can happen at any time, often without warning symptoms, and is more consequential in older adults.

Activa is contraindicated in patients with established congestive heart failure, pre-existing ischaemic heart disease, or cerebrovascular disease. It is also restricted for use in the setting of coronary artery bypass graft (CABG) surgery and in the last trimester of pregnancy.

Overdose and Emergency Response

The official regulatory profile for Activa (Diclofenac Sodium) states that in cases of suspected overdose, there is an explicit requirement to seek immediate medical attention. This instruction is mandatory due to the risk of severe outcomes and the documented absence of a specific antidote for this class of medicine.

Documented manifestations of an overdose primarily affect the gastrointestinal and central nervous systems. Symptoms may include nausea, vomiting, epigastric pain, headache, drowsiness, dizziness, and ringing in the ears (tinnitus). Severe exposure can escalate to life-threatening clinical sequelae. These include major systemic issues such as seizures, coma, acute renal failure, and severe gastrointestinal hemorrhage or perforation.

Regulatory documents highlight that elderly patients are at a greater risk for serious gastrointestinal events in this setting. The emergency management is symptomatic and supportive. Intervention focuses on continuous monitoring of vital signs, fluid administration, and consideration of procedural steps like administering activated charcoal or a laxative if the overdose occurred recently. Urgent medical help must be sought immediately upon suspicion of overdose or if an excessive amount has been taken, as continuous observation and specialized care may be required.

Therapeutic Uses of Activa

What Activa Treats: Main Uses and Benefits

Activa is commonly used to help with symptomatic relief for various forms of mild to moderate discomfort. Medications of this type serve as both pain relievers and fever reducers. It is applied in contexts that involve acute or unstable symptom patterns, such as headaches, muscle aches, dental pain, menstrual cramps, and common aches associated with the cold or flu.

This medication helps address symptom clusters related to physical discomfort and inflammatory or irritative processes, offering support that helps to ease the overall symptom burden during periods of heightened symptoms. It is relevant in contexts involving heightened systemic burden, such as when a high temperature is present. The use of this medication offers symptomatic relief that helps patients cope more steadily with difficult episodes.


Quick Fact: Relief for Fever and Pain

By supporting the management of these manifestations, Activa contributes to improved comfort and stability when symptoms become more noticeable, and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

The eligibility for using Activa, whose active ingredient is Diclofenac Sodium, is strictly defined by regulatory documents, which establish clear criteria for prohibition, restriction, and conditional use.

Contraindicated Populations

Use of the medicine is contraindicated in patients with:

  • Known hypersensitivity to Diclofenac or any other Nonsteroidal Anti-Inflammatory Drug (NSAID) [Source 1.2].
  • Active gastrointestinal ulceration, bleeding, or perforation [Source 1.2].
  • Severe, established organ failures (e.g., severe hepatic or renal failure) [Source 1.1].
  • Established cardiovascular diseases, including Congestive Heart Failure (NYHA Class II–IV), Ischemic Heart Disease, or Cerebrovascular Disease [Source 1.2, 1.7].
  • The setting of Coronary Artery Bypass Graft (CABG) surgery [Source 1.2, 1.3].

Age and Physiological Restrictions

Population Eligibility Status (Official Labeling)
Late Pregnancy Contraindicated in the last trimester (from about 30 weeks gestation) [Source 1.2]. Use between 20 and 30 weeks requires restriction to the lowest effective dose [Source 1.2].
Pediatric Patients Use is not established or not recommended in young children, with specific minimum age limits (e.g., ge12 or ge16 years) often applied based on the formulation [Source 1.5, 2.3].
Older Adults Use is permitted, but requires caution due to increased susceptibility to adverse gastrointestinal and renal events [Source 1.4].
Lactating Women Use is generally not recommended as the drug is excreted in breast milk [Source 3.2].

Conditional Eligibility

Patients with certain conditions, such as mild-to-moderate renal or hepatic impairment, or a history of gastrointestinal ulceration, may use the medicine but require caution and close monitoring as defined in regulatory warnings [Source 1.4, 2.7].

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

Activa (Diclofenac Sodium) has an officially documented interaction profile based on pharmacokinetic and pharmacodynamic constraints found in government regulatory sources.

Contraindicated and High-Risk Combinations Co-administration with other systemic NSAIDs, including COX-2 selective inhibitors, is generally not recommended due to the potential for additive gastrointestinal (GI) undesirable effects. Similarly, combining with Aspirin is advised against due to an increased risk of serious GI events. Use is formally contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Interactions Affecting Bleeding and Drug Levels A primary pharmacodynamic constraint is the increased risk of bleeding or hemorrhage when Activa is combined with anticoagulants, anti-platelet agents, and SSRIs/SNRIs. Activa may also diminish the antihypertensive and natriuretic effects of co-administered diuretics and other antihypertensive agents.

Activa affects the clearance of several specific medicines, leading to potential elevation of plasma concentrations for Lithium, Digoxin, and Methotrexate through reduced renal clearance. This profile also notes that CYP2C9 inhibitors (e.g., Voriconazole) can significantly enhance Activa's own plasma exposure.

Population-Specific Notes Regulatory documents specify that elderly patients face a greater risk for serious GI events with co-administered high-risk medications. Furthermore, caution is noted for patients with impaired renal or cardiac function receiving diuretics, due to the risk of renal function deterioration.

Mechanism of Action

Activa (Diclofenac Sodium) functions by interfering with molecular targets and defined biochemical pathways. Its action is centered on the inhibition of the Cyclooxygenase ( COX) enzyme system, which catalyzes the synthesis of prostanoids, potent regulators of local vascular and cellular responses.

Primary Molecular Engagement: COX Inhibition

This domain covers the core interaction of the drug with its primary targets: the COX-1 and COX-2 enzymes. As a non-selective competitive inhibitor, Diclofenac suppresses the conversion of arachidonic acid into prostaglandins—the key mediators that drive inflammatory and nociceptive signaling.

Pathway Modulation: Peripheral Nociceptive Signaling

By limiting prostaglandin synthesis in peripheral tissues, the drug engages mechanisms that modulate the peripheral nociceptive signaling pathway. This action directly reduces the sensitization of nerve endings, decreasing neuronal excitability and resulting in a functional attenuation of peripheral nociceptive signaling. Concurrently, reducing pro-inflammatory prostaglandins limits associated vascular permeability and swelling, leading to a functional reduction in PGE2-mediated vascular permeability and local edema.

️ Central System Adjustment: Thermoregulation

The mechanism extends to a central system, specifically acting on the hypothalamic thermoregulatory center. By suppressing PGE2 synthesis within the CNS, the drug removes the prostaglandin-mediated signal that raises the body's thermoregulatory set point, leading to predictable physiological shifts that return the thermal set point to a non-febrile level.

Dosage and Administration Information

The administration of this medicine is defined for use in opioid-tolerant adult patients (e.g., those taking at least 60 mg of oral morphine daily) who require around-the-clock opioid therapy. It is intended for use only for episodes of breakthrough pain.

Administration Method

  • Route: Sublingual (under the tongue). The tablet must be placed directly under the tongue in the deepest part of the sublingual cavity and allowed to dissolve completely. It must not be swallowed, chewed, sucked, or crushed.
  • Timing: The tablet is taken at the onset of a breakthrough pain episode. Patients should not eat or drink anything until the tablet has completely dissolved.

Dosing Protocol

Administration Step Official Instruction
Initial Dose The starting dose for all patients is 100 micrograms (mcg) for each pain episode.
Dose Titration The dose is individually adjusted upward over several episodes of breakthrough pain until an effective, tolerable dose is found. The effective dose is not determined by the dose of the background opioid.
Maximum Dosing (Per Episode) A second tablet of the same strength may be administered 15 to 30 minutes after the first dose, only if instructed by a healthcare provider and if the pain is not relieved.
Frequency Constraint Patients must wait a minimum of 2 to 4 hours before treating a new episode of breakthrough pain.
Daily Limit Consumption must be limited to four or fewer breakthrough pain episodes per day.

These rules ensure the medicine is used only as a rapid-acting supplement for acute pain flares in a highly controlled manner, with the dose determined through individual titration and not by simple conversion from other opioids.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Activa (Diclofenac Sodium)

Diclofenac was evaluated in research contexts where outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states are present. The research is primarily based on formal clinical trials and systematic reviews, which help show what has been observed so far, according to regulatory bodies.


Evidence for Use in Osteoarthritis Pain

A significant body of research has explored Activa for conditions marked by functional limitations like osteoarthritis (OA). The foundation of this evidence relies on Randomized Controlled Trials (RCTs) where Diclofenac (in both tablet/capsule and gel forms) was studied for its impact on patient-reported outcomes describing perceived discomfort.

Studies explored changes in pain intensity and changes in daily functioning or activity level. Research focused on populations of adults and older adults with diagnosed OA. While many short-term RCTs have focused on measurements over 4 to 12 weeks, longer-term outcome patterns are not fully established by these controlled trials. Evidence observing symptom patterns over extended periods comes largely from large-scale retrospective observational studies and registry data.


Evidence for Use in Acute Pain and Injury

The research examined Activa’s short-term outcomes related to pain score reduction for conditions associated with acute or disruptive episodes, such as short-term injuries or musculoskeletal discomfort. The core outcomes monitored in this setting include the time to onset of measured pain score reduction and the measured change in pain intensity over the initial few hours following administration.

Follow-up durations were limited, focusing on outcomes within hours up to a few days. Therefore, the research provides limited insight into what happens if the acute discomfort persists or recurs over the following weeks. Additionally, comparative evidence is lacking for certain specific formulations or doses against all available alternatives in the literature.


Evidence in Special Populations and Uncertainty

Research has explored Diclofenac's use in various populations, notably older adults in the context of chronic conditions like osteoarthritis. These studies monitor physiological and functional outcomes in this age group, and one long-term post-hoc analysis suggested tolerability patterns in older patients with pre-existing risk factors.

However, for populations such as children or pregnant individuals, the evidence base remains significantly constrained or non-existent in the published controlled literature. Furthermore, subgroup findings are uncertain regarding measured outcome patterns for individuals with multiple underlying conditions or those with the highest risk profiles.

Frequently Asked Questions (FAQ)

Common questions about Activa (FAQ)


Q: How quickly does Activa start to work for pain relief?

A: According to official product information, the time it takes for Activa to start working can vary. For some immediate-release formulations, effects may be observed within approximately one hour of administration, but the exact onset time depends on the specific condition being treated and the type of Activa product used.

Q: How long do the effects of Activa typically last?

A: While oral forms of this type of medicine often provide relief for 3 to 6 hours, the exact duration of the pain-relieving effects will depend on the dose and the specific formulation prescribed, such as whether it is an immediate-release or sustained-release product.

Q: Is it better to take Activa before or after eating food?

A: If Activa causes stomach upset, official information often recommends taking it with food, milk, or immediately after a meal to help reduce discomfort. However, it is important to check the specific instructions for certain formulations, as some may be directed to be taken on an empty stomach.

Q: Can Activa be taken long-term for chronic conditions like arthritis?

A: Activa is approved for chronic conditions like arthritis, but regulatory warnings emphasize that patients should use the lowest effective dose for the shortest duration possible. This is because the risks of serious adverse events, particularly those related to the heart and stomach, are thought to increase with prolonged, high-dose use.

Q: Does Activa cause drowsiness or affect driving ability?

A: Official information states that Activa may cause side effects such as dizziness, drowsiness, a spinning sensation (vertigo), or blurred vision. If these effects occur, official patient safety information advises avoiding activities such as driving or operating machinery.

Q: Can Activa interact with over-the-counter pain medications or supplements?

A: Regulatory warnings advise against combining Activa with other systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including over-the-counter NSAIDs like ibuprofen or naproxen. Combining these medicines, even with low-dose aspirin, greatly increases the risk of serious side effects like gastrointestinal bleeding.

Q: Does Activa affect blood pressure?

A: Regulatory documents include warnings that Activa can cause a new onset of high blood pressure or worsen pre-existing high blood pressure. For patients using Activa, regulatory guidance emphasizes the importance of monitoring blood pressure, especially when starting treatment.

Q: Can Activa cause fluid retention or swelling in the legs?

A: Yes, fluid retention, which can lead to swelling, especially in the ankles, feet, or hands (edema), has been reported in association with the use of this class of medicine.

Q: Does Activa thin the blood or affect clotting?

A: While Activa is not a primary blood thinner, it can inhibit the function of blood platelets, which are essential for clotting. This action can increase the risk of bleeding or hemorrhage, especially if it is taken with other medicines that affect blood clotting.

Q: Is it common for doctors to prescribe Activa for joint stiffness?

A: Activa is indicated to relieve symptoms of inflammatory conditions such as arthritis, which often include inflammation, swelling, stiffness, and joint pain. Therefore, it may be used in managing the functional limitations caused by joint stiffness.

Q: Can Activa be taken with anti-acids, and should they be timed apart?

A: To potentially reduce the risk of stomach upset, patients sometimes take Activa with food or milk, and some may use stomach protection medicines like antacids. Patients who use antacids or other stomach protectors should consult their healthcare provider regarding the optimal timing for taking these medicines together.

Q: Can Activa be taken for a regular headache or migraine?

A: Depending on the specific Activa formulation, it may be indicated for the short-term relief of general pain. Some specific formulations are also approved for the treatment of acute migraine attacks, including those with or without an aura.

Q: What happens if I miss a dose of Activa?

A: Official patient instructions provide guidance on what to do if a dose is missed, which generally involves taking it as soon as possible or skipping it if the next dose is due soon. Patients are advised to refer to the specific dosing instructions provided with their medicine.

Q: Is it normal to feel a mild stomach ache after taking Activa?

A: Abdominal pain or a mild stomach ache is listed as a common side effect in official safety reports. Taking the medicine with food or milk is sometimes suggested to help reduce stomach discomfort.

Q: What are the potential risks of taking Activa for a prolonged time?

A: Regulatory warnings state that the risk of serious adverse events, including cardiovascular thrombotic events (such as heart attack or stroke) and internal bleeding or ulcers in the stomach, increases when Activa is used at higher doses or for prolonged periods.

Q: Is it safe to drink alcohol while taking Activa?

A: Official warnings state that combining Activa with alcohol can significantly increase the risk of stomach bleeding and other serious gastrointestinal side effects. It is important for patients to discuss alcohol use with their healthcare provider.

Q: What does it mean that Activa works by 'blocking chemical substances'?

A: Activa works by reducing the effects of an enzyme called Cyclooxygenase ( COX). This action effectively blocks the production of certain chemical substances called prostaglandins, which are the main messengers responsible for causing pain signals and swelling.

Q: Why are there different formulations of Activa, like tablets and injections?

A: Different forms, such as tablets, capsules, gels, and injections, are available to suit various therapeutic needs. For example, injections are used for rapid systemic action, gels are used for targeted local relief, and tablets are used for general systemic relief.

Q: Why is Activa sometimes prescribed in a higher strength, like 100mg?

A: Higher strengths may be used for initial treatment or for managing more severe or persistent inflammatory conditions, such as rheumatoid arthritis. However, for long-term treatment, the total daily dose is typically advised to be kept at the lowest effective level.

Q: What is the purpose of the 'SR' or 'Sustained Release' version of Activa?

A: Sustained Release (SR) or Prolonged Release formulations are specifically designed to release the medication into the body gradually over an extended period. This mechanism may allow the drug to be taken less frequently, often once or twice a day, to potentially provide more continuous relief.

Q: What are the specific conditions that make Activa use not recommended (contraindications)?

A: Official information lists several conditions that strictly prohibit the use of Activa (contraindications). These include established severe heart disease like heart failure, active stomach ulcers or bleeding, severe liver or kidney failure, a history of allergic reactions to any NSAID, and use during the last trimester of pregnancy.

Q: Can Activa cause an allergic reaction, and what are the signs to watch for?

A: Activa can cause hypersensitivity reactions (allergic reactions), which are rare but potentially serious. Signs of a severe allergic reaction to watch for include swelling of the face, lips, tongue, or throat, hives, a severe spreading rash, or difficulty breathing.

Q: Is Activa safe for people with a history of asthma or respiratory issues?

A: Activa is formally contraindicated (should not be used) in patients who have a history of asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs, as its use can potentially trigger or worsen those respiratory symptoms.

Q: What should I do if Activa doesn't seem to be working for my pain?

A: Regulatory guidance suggests that the dose should always be maintained at the lowest level that provides effective pain control. If a patient finds that the medicine is providing no benefit, it is important for them to speak with a healthcare professional before making any changes to their treatment.

Q: Can Activa cause dizziness or lightheadedness?

A: Dizziness is listed as a common side effect in official safety reports. Other effects on the central nervous system, such as feeling sleepy (somnolence) or having a spinning sensation (vertigo/lightheadedness), have also been reported.

Q: Why might a doctor suggest a lower starting dose of Activa for some patients?

A: The lowest effective dose is always recommended to minimize risks. Regulatory documents specifically note that certain populations, such as elderly patients or those with low body weight, may be advised to start at a lower dose due to their increased sensitivity and a greater risk for adverse effects.

Q: Is Activa used for menstrual cramps (dysmenorrhea)?

A: Yes, official indications for Activa include the treatment of pain associated with menstrual cramps, which is also known as primary dysmenorrhea.

Q: Do different brands of Activa contain the same main ingredient?

A: Yes, different brands that are marketed as containing Diclofenac Sodium (the active ingredient in Activa) contain the same core chemical substance. All these branded and generic products must meet the same stringent regulatory standards for quality, strength, and efficacy.

Q: Does Activa affect fertility or the ability to conceive?

A: Official warnings state that Activa may impair female fertility and is generally not recommended for women who are trying to conceive or are undergoing investigations for infertility. For individuals having difficulty conceiving, a healthcare provider may consider discontinuation of the medicine.

Q: Is it normal to see a rash develop a few days after starting Activa?

A: Developing a rash is listed as a common side effect in official safety reports. However, it is important to seek immediate medical attention if the rash is severe, spreads quickly, or is accompanied by other serious signs like fever or blistering.

Q: Can Activa be used for pain from sports injuries like sprains?

A: Yes, Activa is indicated for the relief of pain and inflammation associated with a variety of soft tissue injuries, which include common sports injuries such as sprains, strains, and tendonitis.

How should Activa be stored and disposed of?

Activa (Diclofenac Sodium) formulations require strict adherence to official storage and disposal instructions to maintain product integrity and prevent unintended exposure.

Storage Requirements

Condition Regulatory Stipulation
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), away from excess heat.
Protection Keep the container tightly closed and protect the medicine from moisture and freezing. Delayed-release tablets must be dispensed in a light-resistant container.
Child Safety Keep out of the reach of children. The best disposal option is a drug take-back program.

Disposal Instructions

Expired or unused Activa should not be flushed down the toilet or poured down the sink unless explicitly instructed by the label. The primary method for disposal is using a drug take-back location or following the home disposal method for non-flushable medicines, which involves mixing the drug with an undesirable substance (e.g., used coffee grounds) and sealing it in a container before placing it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Activa found in:

A-Z Index: